The Interim Phase II/III clinical trial data of COVAXIN on Healthy Volunteers aged 2 to 18 years submitted by M/s Bharat Biotech was deliberated in the meeting of Subject Expert Committee (SEC) on 26.08.2021 & 11.10.2021. The committee recommended for grant of market authorization for age group of 2 to 18 years for Restricted Use in Emergency Situation subject to various conditions. This recommendation is being examined and additional information has been requested at the level of Central Drugs Standard Control Organisation (CDSCO).

CDSCO has also approved COVID-19 vaccine (ZyCoV-D) of M/s Cadila Healthcare for restricted use in emergency situation in the age group 12 years andabove.

The Union Minister of State for Health and Family Welfare, Dr Bharati Pravin Pawar stated this in a written reply in the Rajya Sabha.

****

MV/AL

HFW/COVID-19 VACCINATION FOR CHILDREN/30th November2021/6

(Release ID: 1776531)